Pine Bark (Pycnogenol)

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph exists for pine bark or Pycnogenol

ESCOP

• No ESCOP monograph has been published for pine bark extract

EMA/HMPC (European Medicines Agency)

• No EMA/HMPC monograph has been published for Pinus pinaster bark
• Note: The absence of a monograph reflects the lack of traditional use documentation meeting EMA criteria, not a negative evaluation of the clinical evidence

Regulatory Context

• France: Pycnogenol has been used as a prescription medication for CVI since the 1970s (Flavan brand)
• Germany: Available as a dietary supplement; not classified as a traditional herbal medicine
• US: Marketed as a dietary supplement; GRAS (Generally Recognized as Safe) status granted by FDA for use in foods and beverages
• Italy: Available as a dietary supplement
• Japan: Extensively marketed and used as a dietary supplement

Agreement/Disagreement Between Bodies

• Notable absence: Despite extensive clinical evidence, no major European regulatory body has published a monograph. This is unusual for a botanical with 100+ clinical trials
• Reason: Pycnogenol is a modern standardized extract (first commercialized in the 1970s) and does not have the centuries-long traditional use history that typically supports Commission E or EMA monographs
• French exception: Historical prescription use for CVI in France provides some quasi-regulatory recognition

Conditions Treated

Primary (Strong Evidence)

• Chronic venous insufficiency (CVI): Multiple RCTs demonstrate significant reductions in leg edema, heaviness, pain, and improved microcirculation; comparable or superior to compression stockings in some studies
• Hypertension / blood pressure reduction: Meta-analysis of 27 RCTs shows significant reductions in both systolic (-2.26 mmHg) and diastolic (-2.62 mmHg) blood pressure

Secondary (Moderate Evidence)

• Endothelial dysfunction: Improvement in endothelial function demonstrated in hypertensive patients (Liu et al. 2004)
• Type 2 diabetes / blood glucose management: Several RCTs show modest HbA1c and fasting glucose reductions as adjunctive therapy
• Venous microangiopathy: Improved microcirculation parameters in multiple studies
• Skin aging and hyperpigmentation: Several RCTs show improved skin elasticity and reduced melasma

Traditional/Historical (Limited or Emerging Evidence)

• Cognitive function and ADHD in children
• Asthma and allergic rhinitis
• Erectile dysfunction
• Jet lag and travel-related edema
• Menstrual pain (dysmenorrhea)
• Osteoarthritis and joint health
• Retinal microangiopathy (diabetic retinopathy)
• Oral health (gingival bleeding)

Mechanism of Action

Primary Mechanisms

Antioxidant:

• Procyanidins are potent free radical scavengers, with antioxidant capacity significantly exceeding that of vitamins C and E in vitro
• Pycnogenol recycles oxidized vitamin C and regenerates vitamin E
• Increases intracellular glutathione levels and upregulates antioxidant enzyme expression (SOD, GPx)

Anti-inflammatory:

• Inhibits NF-kB activation, reducing expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)
• Inhibits COX-1 and COX-2 enzymes (without the gastric side effects of synthetic COX inhibitors)
• Inhibits 5-lipoxygenase (5-LOX) and reduces leukotriene synthesis
• Reduces C-reactive protein (CRP) in clinical studies

Vascular protection:

• Strengthens capillary walls by binding to collagen and elastin in the vascular endothelium, increasing resistance to degradation by elastase and collagenase
• Improves endothelial function by increasing nitric oxide (NO) production via enhanced endothelial nitric oxide synthase (eNOS) expression
• Reduces platelet aggregation (comparable to aspirin at 200 mg but without increased bleeding time)
• Decreases vascular permeability, reducing edema formation

Secondary Mechanisms

Metabolite Activity

• Pycnogenol procyanidins are metabolized by gut microbiota to smaller phenolic acids (including delta-(3,4-dihydroxy-phenyl)-gamma-valerolactone, known as M1) that retain biological activity
• Metabolite M1 has demonstrated matrix metalloproteinase (MMP) inhibition, relevant to vascular protection and joint health

Clinical Evidence Summary

Volume of Evidence

• Extensive. Over 100 clinical studies published, including 39+ randomized, double-blind, placebo-controlled trials involving over 2,000 subjects. However, the majority of studies originate from a relatively small group of investigators (primarily Belcaro, Cesarone, and colleagues at the Chieti-Pescara University, Italy) with consistent industry support.

Key Studies

Chronic Venous Insufficiency

Blood Pressure

Blood Glucose

Evidence Gaps

• Most studies are small (N < 100) and short-term (2-3 months)
• The evidence base is dominated by a single research group with industry ties
• Large, independent, multi-center confirmatory trials are lacking
• No Cochrane systematic review dedicated to Pycnogenol
• Head-to-head comparisons with established pharmaceutical treatments are limited
• Long-term safety and efficacy data (>12 months) are sparse

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to pine bark or any Pinaceae species
• Autoimmune conditions (theoretical concern: may stimulate immune function; caution advised in MS, lupus, rheumatoid arthritis)
• Pre-surgical: discontinue at least 2 weeks before elective surgery (mild antiplatelet effect)

Drug Interactions

• Anticoagulants/antiplatelets: Pycnogenol has mild antiplatelet activity (inhibits platelet aggregation); theoretical additive effect with warfarin, aspirin, clopidogrel. One pharmacokinetic study showed no significant interaction with warfarin, but caution is advised
• Antihypertensives: Additive blood pressure-lowering effect possible; monitor blood pressure
• Hypoglycemic agents: Additive blood glucose-lowering effect possible; monitor blood glucose when combined with diabetes medications
• Immunosuppressants: Theoretical antagonism due to immune-modulating properties of Pycnogenol
• CYP interactions: In vitro data suggests potential CYP1A2 and CYP2C9 modulation, but clinical significance has not been established

Side Effects

• Generally very well tolerated in clinical trials; adverse event rates comparable to placebo
• Mild gastrointestinal discomfort (nausea, stomach upset) — reduced by taking with meals
• Headache and dizziness (uncommon)
• In women using Pycnogenol for dysmenorrhea: acne and dysfunctional uterine bleeding reported rarely
• No hepatotoxicity or nephrotoxicity observed in clinical studies

Pregnancy/Lactation

• Pregnancy: Not recommended during pregnancy; insufficient safety data in pregnant women. No teratogenicity observed in animal studies
• Lactation: Insufficient data; avoid during breastfeeding
• Children: Studied in children (ages 6-14) for ADHD at 1 mg/kg/day with acceptable safety profile; however, routine use in children is not established

Clinical Dosage

Standard Dosage Forms

Key Dosing Notes

• Loading dose: Some practitioners recommend a higher dose (200-300 mg/day) for the first week, then maintenance at 100-150 mg/day; this approach has not been formally studied
• Onset of action: Benefits for CVI typically appear within 4-8 weeks; blood pressure effects may take 4-12 weeks
• Duration: Most studies lasted 2-3 months; long-term use appears safe based on available data but is not extensively documented beyond 6 months
• Product specificity: The vast majority of clinical evidence is based on the branded Pycnogenol extract; other pine bark extracts may differ in composition and may not be directly comparable

Sources

• Frontiers in Nutrition. Pycnogenol French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. Front Nutr. 2024;11:1389374
• BMC Complement Med Ther. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complement Med Ther. 2025;25:4819
• Arcangeli P. Pycnogenol in chronic venous insufficiency. Fitoterapia. 2000;71(3):236-244
• Cesarone MR, et al. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine. 2010;17(11):835-839
• Cesarone MR, et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol. Angiology. 2006;57(5):569-576
• Belcaro G, et al. Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol. Minerva Cardioangiol. 2019;67(4):280-287
• Liu X, et al. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004;74(7):855-862
• Zibadi S, et al. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008;28(5):315-320
• Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40(4):158-168
• National Center for Complementary and Integrative Health (NCCIH). Pine Bark Extract fact sheet
• LiverTox: Pine Bark. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Connections

• Compare with Horse Chestnut as the gold-standard herbal treatment for chronic venous insufficiency; horse chestnut (aescin) has Cochrane-level evidence and full European regulatory approval, while Pycnogenol has extensive trial data but no regulatory monographs
• Compare with Red Vine Leaf as another OPC-rich botanical for CVI; red vine leaf has an EMA monograph for CVI symptoms
• Related to Bilberry as a fellow anthocyanidin/proanthocyanidin-rich extract used for microvascular protection and venous health
• Compare with Ginkgo as a vascular-protective botanical; both improve microcirculation, but ginkgo acts primarily through PAF antagonism while Pycnogenol acts through collagen stabilization and eNOS activation
• Compare with Hawthorn for cardiovascular applications; hawthorn has stronger evidence for heart failure, while Pycnogenol has stronger evidence for peripheral venous conditions
• The OPC content links Pycnogenol mechanistically to Grape Seed Extract, which contains similar procyanidins from a different botanical source